寡转移性激素敏感性前列腺癌患者接受雄激素剥夺与外照射放疗的II期前瞻性试验长期结局
该II期前瞻性试验从2006至2011年纳入29例寡转移性激素敏感性前列腺癌患者,接受36周雄激素剥夺治疗(黄体生成素释放激素激动剂+比卡鲁胺)及对所有可见转移灶的外照射放疗(最高53 Gy)。中位随访9.9年,中位总生存9.7年,中位无进展生存1.9年;初诊转移患者中位无进展生存2.0年,优于寡复发的1.8年(P=0.04)。
要点
- 29例患者中15例初诊转移、14例寡复发,21例(72.4%)有骨转移,中位转移灶数目为1个(范围1-5)。
- 全组中位无进展生存1.9年(95%CI 1.6-2.2),中位总生存9.7年(95%CI 5.8-未达到)。
- 初诊转移患者中位无进展生存2.0年(95%CI 1.3-6.0),显著优于寡复发患者的1.8年(95%CI 1.0-2.0)(P=0.04)。
核心结论
- 本试验结果与其他已报道的寡转移性激素敏感性前列腺癌研究相比具有优势,并为其长期结局提供了新见解。
研究设计与样本
- II期前瞻性试验,2006至2011年纳入29例寡转移性激素敏感性前列腺癌患者,转移灶数目1至5个。
- 患者接受36周雄激素剥夺治疗(黄体生成素释放激素激动剂+比卡鲁胺)及对所有可见转移灶的外照射放疗,最高53 Gy。
- 必要时原发肿瘤或前列腺床分别接受外照射放疗最高78 Gy或66 Gy。
主要发现
- 29例患者中15例为初诊转移、14例为寡复发,21例(72.4%)有骨转移,中位转移灶数目1个(范围1-5)。
- 外照射放疗照射52个病灶(38个骨、12个盆腔淋巴结、2个非盆腔淋巴结),最高53 Gy(范围47-66)。
- 中位随访9.9年(范围0.2-14.4),中位总生存9.7年(95%CI 5.8-未达到),中位无进展生存1.9年(95%CI 1.6-2.2)。
- 初诊转移患者中位无进展生存2.0年(95%CI 1.3-6.0),显著优于寡复发患者的1.8年(95%CI 1.0-2.0)(P=0.04)。
- 仅有淋巴结转移患者中位无进展生存5.8年(95%CI 1.2-未达到),与骨转移患者的1.8年(95%CI 1.3-2.0)相比数值上更优(P=0.13)。
关键数值与推荐
- 末次随访时,17例患者(58.6%)所有外照射放疗照射的转移灶均局部控制。
- 局部进展的转移灶既往控制的中位时间为3.5年(范围1.7-10.5)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: External beam radiation therapy (EBRT) to oligometastases may improve outcomes in patients with oligometastatic hormone-sensitive prostate cancer (oHSPC). Follow-up on this cohort has been limited to <5 years and prospective data on de novo patients with oHSPC are lacking. We reviewed the long-term outcomes of patients with oHSPC treated with EBRT and androgen deprivation therapy on a prospective trial. METHODS AND MATERIALS: From 2006 to 2011, patients with oHSPC with 1 to 5 metastases received 36 weeks of androgen deprivation therapy (luteinizing hormone-releasing hormone agonist + bicalutamide) and up to 53 Gy to all visible metastases. When indicated, the primary tumor or prostate bed was treated with EBRT up to 78 or 66 Gy, respectively. RESULTS: Twenty-nine patients were treated: 15 de novo, 14 oligorecurrent, and 21 patients (72.4%) had bone metastases. Median number of metastases per patient was 1 (range, 1-5). EBRT was administered to 52 lesions (38 bone, 12 pelvic lymph nodes [LNs], 2 nonpelvic LNs) up to 53 Gy (range, 47-66). Median follow-up was 9.9 years (years; range, 0.2-14.4). Median overall survival was 9.7 years (95% confidence interval [CI], 5.8-not reached). Median progression-free survival was 1.9 years (95% CI, 1.6-2.2). Patients who presented with prostate cancer-defined de novo metastases had significantly improved (P = .04) median progression-free survival (2.0 years; 95% CI, 1.3-6.0) compared with oligorecurrent patients (1.8 years; 95% CI, 1.0-2.0). Patients who presented with LN-only metastases had numerically improved (P = .13) median PFS (5.8 years; 95% CI, 1.2-not reached) compared with patients with bony metastases (1.8 years; 95% CI, 1.3-2.0). At last follow-up, 17 patients (58.6%) had local control of all EBRT-treated metastases. The metastases that locally progressed had previously been controlled for median 3.5 years (range, 1.7-10.5). CONCLUSIONS: Our results compare favorably with other reported studies of patients with oHSPC and provide new insights into their long-term outcomes.
引用
- Hao C, Ladbury C, Lyou Y, et al. Long-Term Outcomes of Patients on a Phase II Prospective Trial of Oligometastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation and External Beam Radiation. Int J Radiat Oncol Biol Phys. 2022. PMID: 35803445. doi:10.1016/j.ijrobp.2022.06.085
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。